CTSO insider trading
NasdaqCM HealthcareCytosorbents Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Company website: www.cytosorbents.com
CTSO insider activity at a glance
FilingIQ has scored 361 insider transactions for CTSO since Dec 31, 2008. The most recent filing in our index is dated Nov 18, 2025.
Across the full history, 61 open-market purchases
and 63 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CTSO insider trades is 49.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CTSO?
- FilingIQ tracks 361 Form 4 insider transactions for CTSO (Cytosorbents Corp), covering filings from Dec 31, 2008 onwards. 0 of those were filed in the last 90 days.
- Are CTSO insiders net buyers or net sellers?
- Across the full Form 4 history for CTSO, 61 transactions (17%) were open-market purchases and 63 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CTSO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CTSO in?
- Cytosorbents Corp (CTSO) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $43.34M.
Methodology & sources
Every CTSO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.